NCT04824339

Brief Summary

This project will assess the efficacy of an 8-week virtual exercise program on physical function offered to those with a breast cancer diagnosis currently receiving endocrine therapy. The intervention includes twice-weekly virtual group exercise classes. Participants also complete one to three independent home exercise sessions per week throughout the intervention. Testing will occur virtually at baseline, 8-weeks (at end of program) and follow-up evaluations will be performed at 16-weeks and 12- months after baseline testing. Questionnaires will be administered through REDCap. Exercise sessions and testing will be administered virtually via Zoom.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
132

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 15, 2021

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

March 22, 2021

Completed
10 days until next milestone

First Posted

Study publicly available on registry

April 1, 2021

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2022

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
Last Updated

April 1, 2021

Status Verified

March 1, 2021

Enrollment Period

1.8 years

First QC Date

March 22, 2021

Last Update Submit

March 26, 2021

Conditions

Keywords

ExerciseAdjuvant endocrine therapyBreast cancer survivorVirtual DeliveryReduce side effects

Outcome Measures

Primary Outcomes (1)

  • Physical Function

    Measured by 30 second sit to stand test

    Change from baseline to week 8 (end of intervention)

Secondary Outcomes (10)

  • Medication adherence to endocrine therapy

    Change from baseline at week 8 (end of intervention), 16 weeks and 12-months

  • Health-related quality of life

    Change from baseline at week 8 (end of intervention), 16 weeks and 12-months

  • Usual physical activity levels

    Change from baseline at week 8 (end of intervention), 16 weeks and 12-months

  • Weight in kilograms

    Change from baseline at week 8 (end of intervention), 16 weeks and 12-months

  • Height in metres

    Change from baseline at week 8 (end of intervention), 16 weeks and 12-months

  • +5 more secondary outcomes

Study Arms (2)

Immediate Intervention Group

EXPERIMENTAL

The intervention is an 8-week combined aerobic and resistance program, with virtual, group-based, supervised exercise sessions twice per week (60 min). The intervention also includes optional education on healthy eating.

Behavioral: Immediate Intervention Group

Delayed Intervention Group

EXPERIMENTAL

Usual lifestyle control for 8 weeks and then invited to participate in the exercise intervention.

Behavioral: Delayed Intervention Group

Interventions

This study is a partial cross over study. The intervention is 8 weeks in duration. Participants will be randomized to immediate exercise or delayed exercise, and the delayed exercise group will cross over to the intervention after 8 weeks.

Immediate Intervention Group

This study is a partial cross over study. The intervention is 8 weeks in duration. Participants will be randomized to immediate exercise or delayed exercise, and the delayed exercise group will cross over to the intervention after 8 weeks.

Delayed Intervention Group

Eligibility Criteria

Age19 Years - 75 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Stage I - III breast cancer patients who are treated with curative intent
  • Completed primary treatment, including surgery, radiation therapy and/or chemotherapy
  • Currently receiving adjuvant endocrine therapy (Tamoxifen or an Aromatase Inhibitor) for at least 3 months (to allow for acclimatization) and within 3-years of of staring endocrine therapy.
  • Can read and speak English
  • Has access to a tablet, smartphone, laptop or computer with built-in video camera

You may not qualify if:

  • Not currently receiving endocrine therapy or scheduled to stop within 6 months
  • Diagnosed with stage IV breast cancer
  • Not willing to attend a twice-weekly exercise program virtually for the duration of the study.
  • Not willing to comply with safety measures of virtual programming (to be seen on camera and monitored via video by the instructor)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Clinical Exercise Physiology Lab

Vancouver, British Columbia, V6T 1Z3, Canada

RECRUITING

MeSH Terms

Conditions

Breast NeoplasmsMotor Activity

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesBehavior

Study Officials

  • Kristin L Campbell, PhD

    Department of Physical Therapy

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Kelly Mackenzie, MSc

CONTACT

Aaliya Merali-Dewji, MSc

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

March 22, 2021

First Posted

April 1, 2021

Study Start

March 15, 2021

Primary Completion

December 31, 2022

Study Completion

December 31, 2023

Last Updated

April 1, 2021

Record last verified: 2021-03

Locations